THE WHAT? Johnson & Johnson has announced a proposed comprehensive settlement to resolve the remaining US ovarian talc litigation, following a favourable federal court ruling that questioned plaintiffs’ ability to prove the company’s talc products caused ovarian cancer.
THE DETAILS The proposed agreement is contingent on at least 95% of the remaining claimants participating and would resolve approximately 76,000 outstanding ovarian talc claims. Johnson & Johnson has committed US$5.5 billion towards the settlement, with an initial payment of up to US$3 billion scheduled for 2027 and the remaining payments beginning no earlier than 2028. The proposal follows a Multi-District Litigation (MDL) court ruling that required plaintiffs to demonstrate specific causation after expert witnesses withdrew testimony in two bellwether cases. The company said the settlement would conclude a 15-year legal dispute while maintaining its position that cosmetic talc is safe, does not contain asbestos and does not cause cancer.
THE WHY? The proposed settlement could bring greater certainty to one of the cosmetics industry’s largest and longest-running product liability cases. Resolving the litigation would reduce legal uncertainty for Johnson & Johnson while reinforcing the importance of scientific evidence in product safety claims and mass tort litigation across the beauty and personal care sector.
Source: Johnson & Johnson
